Osteoporosis Management Guidelines

Diagnosis and Assessment

• The American College of Clinical Oncology recommends bone mineral density (BMD) testing with central/axial dual-energy x-ray absorptiometry (DXA) for patients with risk factors for osteoporotic fracture 1
• DXA testing should be performed in all women 65 years and older, and in postmenopausal women younger than 65 with risk factors, as suggested by clinical guidelines 2
• Fracture risk assessment should include tools such as FRAX to quantify fracture risk beyond BMD alone, according to the Journal of Clinical Oncology 3, 2
• Patients prescribed medications that cause bone loss or whose BMD is near treatment threshold should have BMD testing every 2 years, as recommended by the Journal of Clinical Oncology 1, 4

Non-Pharmacologic Interventions

• Patients should consume adequate calcium (1,000-1,200 mg/day) and vitamin D (at least 800-1,000 IU/day) through diet or supplements, as recommended by the Journal of Clinical Oncology 1, 3, 2
• A multi-component exercise approach has demonstrated significant benefits for BMD in middle-aged and older men, according to Nature Reviews Rheumatology 5
• Exercise reduces the risk of falls by 23%, emphasizing its potential benefits on musculoskeletal health, as reported by Nature Reviews Rheumatology 5
• Patients should engage in a combination of exercise types, including balance training, flexibility/stretching exercises, endurance exercise, and resistance/progressive strengthening exercises, as recommended by the Journal of Clinical Oncology 1, 6, 5

Pharmacologic Interventions

• Pharmacologic therapy should be offered to patients with T-scores of -2.5 or less in the femoral neck, total hip, or lumbar spine, or with a 10-year probability of ≥20% for major osteoporotic fractures or ≥3% for hip fractures based on FRAX, according to the Journal of Clinical Oncology 1, 6, 2
• Bisphosphonates (oral or IV) are first-line therapy for most patients with significant fracture risk, as suggested by Praxis Medical Insights 2
• Denosumab (subcutaneous) is an alternative for patients at high risk of fracture or who cannot tolerate bisphosphonates, according to Praxis Medical Insights 2
• Hormonal therapies (e.g., estrogens) are generally avoided in patients with hormone-responsive cancers but may be offered along with other bone-modifying agents when clinically appropriate for patients without hormone-responsive cancers, as recommended by the Journal of Clinical Oncology 1

Special Populations

• Cancer survivors may have baseline risks for osteoporosis plus added risks from treatment-related bone loss due to hypogonadism from endocrine therapy or chemotherapy-associated medications, according to the Journal of Clinical Oncology 3, 7
• Specific populations appropriate for bone-modifying agents include premenopausal women receiving GnRH therapies, postmenopausal women receiving aromatase inhibitors, men receiving androgen deprivation therapy, patients with history of bone marrow transplantation, and patients on chronic glucocorticoid use, as recommended by the Journal of Clinical Oncology 1, 6, 4
• A female reference database should be used for densitometric diagnosis of osteoporosis in men, according to Nature Reviews Rheumatology 5

Monitoring

• Repeat DXA every 2 years or as clinically indicated to monitor treatment response, as recommended by the Journal of Clinical Oncology 3, 7
• BMD assessment should not be conducted more frequently than annually, according to the Journal of Clinical Oncology 7
• Patients should be monitored for medication adherence, as up to 64% of men are non-adherent to bisphosphonate therapy by 12 months, as reported by Nature Reviews Rheumatology 5

Osteoporosis Management Guideline

Non-Pharmacological Management

• The American College of Rheumatology recommends that every patient with osteoporosis must receive calcium (1,000-1,200 mg/day) and vitamin D (800-1,000 IU/day) supplementation, targeting serum 25(OH)D levels ≥30-50 ng/mL, and smoking cessation is mandatory 8
• Limit alcohol to ≤2 servings per day, as recommended by the American College of Rheumatology 8

Pharmacological Treatment

• The American College of Rheumatology conditionally recommends anabolic agents (teriparatide, abaloparatide, or romosozumab) over antiresorptives for very high-risk patients 8
• Teriparatide increases lumbar and hip BMD and decreases vertebral fractures compared to alendronate in glucocorticoid-induced osteoporosis, according to the American College of Rheumatology 8

Special Population: Glucocorticoid-Induced Osteoporosis

• The American College of Rheumatology strongly recommends osteoporosis therapy in addition to calcium and vitamin D for adults ≥40 years taking prednisone ≥2.5 mg/day for >3 months with high or very high fracture risk 8
• Oral bisphosphonates are strongly recommended as first-line for high/very high risk patients by the American College of Rheumatology 8
• For very high risk, the American College of Rheumatology conditionally recommends PTH/PTHrP (teriparatide) over bisphosphonates 8

Common Pitfalls to Avoid

• The American College of Rheumatology recommends ensuring adequate calcium and vitamin D before starting any osteoporosis medication 8
• Do not use anabolic agents after prolonged antiresorptive therapy—the bone anabolic effect is blunted, as noted by the American College of Rheumatology 8

Osteoporosis Treatment Guidelines

Introduction to Osteoporosis Management

• The American College of Rheumatology conditionally recommends against using two different osteoporosis medications concurrently in adults at high or very high fracture risk, due to lack of fracture reduction data, blunted anabolic effects, and increased cost and potential adverse effects 9

Recommended Therapies

• The American College of Rheumatology recommends starting with anabolic agents first (teriparatide, abaloparatide, or romosozumab) for patients with recent vertebral fractures, hip fracture with T-score ≤-2.5, or multiple fractures, followed by antiresorptive therapy (bisphosphonates or denosumab) to maintain gains and prevent rebound bone loss 9, 10
• Oral bisphosphonates are strongly recommended as first-line monotherapy for adults ≥40 years with high fracture risk (T-score ≤-2.5, prior fragility fracture, or FRAX 10-year risk ≥20% major osteoporotic fracture or ≥3% hip fracture) 9, 11

Essential Adjunctive Therapy

• All patients receiving osteoporosis medication must receive calcium (1,000-1,200 mg daily) and vitamin D supplementation (800-1,000 IU daily), targeting serum 25(OH)D levels ≥30-50 ng/mL 9, 12

Special Considerations

• For patients on chronic glucocorticoids (≥2.5 mg/day prednisone for >3 months), very high-risk patients should be conditionally recommended PTH/PTHrP (teriparatide) over bisphosphonates as initial monotherapy, while high-risk patients should be strongly recommended oral bisphosphonates as first-line monotherapy 9, 10

Critical Pitfalls to Avoid

• Never combine two osteoporosis medications simultaneously without compelling individual circumstances, as this contradicts guideline recommendations 9
• Never start antiresorptives before anabolics in very high-risk patients who will eventually need both, as the sequence matters critically for efficacy 9, 10
• Never discontinue denosumab, romosozumab, or PTH/PTHrP without immediately transitioning to antiresorptive therapy, as rebound bone loss and vertebral fractures can occur 9, 10

Monitoring Sequential Therapy

• Repeat DXA every 2 years (or annually if medically indicated) to assess treatment response 12